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Abstract
Introduction: Paracetamol is a frequently used agent in intoxications and known to cause hepatic failure. However, methe-
moglobinemia secondary to paracetamol toxicity has only been described in a handful of case reports and may be an important
determining factor for morbidity and mortality. Methemoglobinemia results in functional anemia with cellular hypoxia. Severe
cases are usually fatal.
Case Presentation: We present a case of survival after severe methemoglobinemia in a 67-year-old female. She was admitted to
the Intensive Care Unit after auto-ingestion of a large amount of paracetamol. Hemoglobin-oximetry showed a methemoglobin
level of 24.6%, treated with intravenous methylene blue, exchange-transfusion, ascorbic acid, and riboflavin. Toxicological screening
revealed a high plasma concentration of paracetamol (611.7 mg/L). Treatment with N-acetylcysteine (NAC) was initiated. The patient
deteriorated and developed acute liver failure, but refused liver transplantation. Furthermore, she developed septic shock with
multi-organ failure and bowel ischemia. In spite of her severe condition and her refusing transplantation, the patient survived.
There was a complete resolution of acute liver failure and she fully recovered from her critical condition.
Conclusions: A case of survival after paracetamol-induced methemoglobinemia is presented. Paracetamol-induced methe-
moglobinemia seems to be a rare (but possibly under-diagnosed) condition. With this report, we would like to focus more attention
on the possibility of methemoglobinemia associated with paracetamol intoxication and emphasize the possible impact on morbid-
ity and mortality. Therefore, we think there should be a low threshold for screening for this rare but hazardous problem when there
is clinical suspicion.
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1. Introduction
Paracetamol is a well-known agent that is frequently
used in intoxications and suicide attempts. Mainly be-
cause it is an over-the-counter drug and the most widely
used analgesic drug in the world (1). Paracetamol poison-
ing is often seen in the Emergency and Intensive Care de-
partments and has been known to cause hepatic failure
due to hepatic necrosis for many years since its clinical in-
troduction in 1955 (2). Methemoglobinemia secondary to
paracetamol toxicity however, has only been described in
4 previous case reports (3-6) and may be an important de-
termining factor for morbidity and mortality. Acquired
methemoglobinemia is a rare disease that has its classic
drug-related causes such as various antibiotics (dapsone
and sulfonamides), local anesthetics and nitrates. Parac-
etamol might be a rare, but important cause should be
added to this list. It could also be a contributing factor
to the severity of methemoglobinemia caused by other
agents. In acquired methemoglobinemia, there is an al-
tered state of hemoglobin, where the Fe2+ ions of the heme
group have been oxidized to Fe3+ ions, which results in the
inability of methemoglobin to bind oxygen resulting in
functional anemia with cellular hypoxia that is often fa-
tal. In this report, we present a case of survival after se-
vere paracetamol-induced methemoglobinemia and acute
liver failure, complicated with septic shock and multi-
organ failure. Our key objective is to raise awareness for
this possible under-diagnosed problem and emphasize the
effect that it might have on our critically ill patients.
2. Case Presentation
A 67-year-old woman was found in her home by a mo-
bile medical team after her husband contacted the emer-
gency services when he could not reach her by phone for
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several hours. The patient was found on her bed in an al-
tered mental state. Scattered in the apartment and on the
patient’s body, there was a white substance, which a sam-
ple was immediately taken and sent to the lab for analy-
sis. The patient had no significant medical history. She did
not take any medication on a regular basis. It was later
revealed that the patient had ingested a large quantity of
paracetamol (more than 10 boxes) mixed with water and
with the intention of committing suicide. At the time of
arrival of the mobile medical team, the patient was con-
fused and had a Glasgow Coma Scale of 9/15 (E3 M5 V1).
She was brought to the emergency department, where she
was further monitored: non-invasive blood pressure was
138/97 mmHg, heart rate 55 beats/minute, saturation 77%
on pulse oximetry with an increased respiratory rate and
body temperature of 36.1°C. Her chest X-ray and electrocar-
diogram (ECG) were within normal limits. Initial arterial
blood gas analysis showed a high anion gap metabolic aci-
dosis (pH 7.23, Anion Gap 25, Na 148 mmol/L, K 3.8 mmol/L,
Cl 115 mmol/L, HCO3- 8.6 mmol/L, pO2 103 mmHg, pCO2 20
mmHg, Base Excess-16, Lactate 5 mmol/L, and glycemia 136
mg/dL). A non-rebreathing mask with 12 L/min of oxygen
was given as well as 1 litre of intravenous (IV) fluids in bolus
(crystalloids). The patient was then transferred to the in-
tensive care unit (ICU) for further diagnostic workup and
monitoring, here a striking blue color of the skin and a
chocolate brown color of the blood was noticed. There-
fore, hemoglobin oximetry was performed that showed a
high methemoglobin level (18.2%). Toxicological screening
(serum and urine) revealed a very high paracetamol con-
centration (> 300 mg/L in urine and 611 mg/L in serum)
after that the treatment with N-acetylcysteine (NAC) was
initiated with a loading dose of 150 mg/kg IV over 30 min-
utes, followed (30 minutes later) by 50 mg/kg IV over 4
hours, followed by 100 mg/kg IV over 16 hours. Other lab re-
sults at the time of the admission showed elevated hepatic
enzymes (alanine aminotransferase (ALT) 252 U/L, aspar-
tate aminotransferase (AST) 451 U/L, lactate dehydrogenase
(LDH) 1715 U/L, ALP 95 U/L, and total bilirubin 1.3 mg/dL).
Coagulation tests were normal at that point (international
normalized ratio (INR) 0.97, platelets 362 10E9/L, and acti-
vated partial thromboplastin time (APTT) 38). Renal func-
tion was normal (with a rather low creatinine 0.21 mg/dL)
and myoglobin was markedly elevated (24,910 ng/mL). Af-
ter that hemoglobin oximetry revealed significant methe-
moglobinemia, the administration of IV methylene blue
(1 mg/kg over 5 minutes) was initiated. Since the toxic
components at the time of presentation were unknown,
5 g of hydroxycobalamine (Cyanokit) was supplementary
administered in light of a high anion gap metabolic aci-
dosis possibly due to cyanide poisoning. Further tests
showed no signs of cyanide poisoning. The initial response
was a decrease in methemoglobin from 18 to 8%. How-
ever, the next morning the methemoglobin level was once
again increased to 13.3% thus the second dose of methy-
lene blue (1 mg/kg IV) was given. Meanwhile, the parac-
etamol concentration decreased to 308 mg/L at 12 hours
post-admission. After reviewing the available literature,
the decision was taken to start intermittent hemodialy-
sis for clearance of paracetamol concomitantly the dose
of NAC was doubled. After hemodialysis, the paraceta-
mol concentration in plasma decreased from 308 to 68
mg/L. Nevertheless, methemoglobin continued to increase
to 24.6%. Therefore, riboflavin (3 × 1 g) and ascorbic acid
(3 × 500 mg) infusions were associated as well as transfu-
sion of 2 units red packed cells after bloodletting of 300 mL
after that methemoglobin levels remained stable around
12%. After 24 hours post-admission the patient developed
acute liver failure with hepatic enzymes and coagulation
tests further deteriorating (INR > 10, APTT > 1300, platelets
130 10E9/L, AST 700 U/L, ALT 566 U/L, and LDH 3496 U/L)
as well as acute kidney injury. She was transferred to a
tertiary care (university) hospital, where liver transplan-
tation could be provided if necessary. Further treatment
of methemoglobinemia with high dose ascorbic acid was
provided there, resulting in further declining levels that
eventually normalized. The patient however, who was still
struggling with depression, refused liver transplantation
and further deteriorated to a septic shock and a state of
multi-organ failure with bowel ischemia. Broad spectrum
antibiotics (piperacillin-tazobactam) and antifungal pro-
phylaxis (fluconazole) were associated and a sigmoid re-
section with abdominal lavage was performed. Prolonged
ventilation was required and during placement of a tra-
cheostomy an iatrogenic perforation of the trachea and
esophagus occurred with a need for repair surgery. Fur-
thermore, a critical illness polyneuropathy was diagnosed.
Despite of this long period of severe illness with multi-
organ failure and all the complications mentioned above
(and the patient’s refusal for liver transplantation), the
acute liver failure recovered completely with supportive
treatment and the patient’s critical condition resolved. She
was transferred to the rehabilitation department of our
hospital 83 days after admission and was discharged from
the hospital 196 days after the admission.
3. Discussion
There are two known forms of methemoglobinemia:
congenital and acquired. The most common congeni-
tal methemoglobinemia is Cytochrome-b5 reductase de-
ficiency, an autosomal recessive genetic disorder that is
caused by a deficiency in the cytochrome-b5 reductase
enzyme. This enzyme is the key factor in one of the
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body’s hemoglobin-reducing pathways, reducing methe-
moglobin back to its healthy form (as further explained
below). Acquired methemoglobinemia is a rare disease.
Its precise incidence and mortality is difficult to be as-
certained from the available literature because the occur-
rence of this disease is quite rare and most cases are pre-
sented only as case reports. Pharmacological agents are
the most common cause of methemoglobinemia in clin-
ical practice. The best known causative agents are local
anesthetics (benzocaine, procaine), antibiotics (dapsone
and sulfonamides), and nitrates (such as nitroglycerin,
nitric oxide) (7). Nitrates can also be present in vegeta-
bles or well water (contaminated with agricultural fertiliz-
ers) and cause methemoglobinemia in newborns and chil-
dren (8). Other toxic products such as paint thinner are
also well known causative agents of methemoglobinemia
(9). Normal hemoglobin contains four heme groups with
iron in the reduced ferrous state (Fe2+). There is an al-
tered state of hemoglobin in acquired methemoglobine-
mia, where the Fe2+ ions of the heme group have been
oxidized to Fe3+ ions, which results in the formation of
methemoglobin. Methemoglobin is unable to bind oxy-
gen. Furthermore, the hemoglobin that is left in the re-
duced state therefore, will have a higher affinity for oxy-
gen and case a left-shift in the oxygen/haemoglobin disso-
ciation curve. These mechanisms result in functional ane-
mia with cellular hypoxia that can be fatal when severe.
In healthy individuals, the formation of methemoglobin
from hemoglobin is an ongoing oxidative process that re-
sults from exposure of hemoglobin to a variety of highly
reactive molecules (oxygen free radicals), produced dur-
ing normal cell metabolism. Yet normal methemoglobin
levels are usually low (< 1%) and are maintained low by en-
dogenous protective pathways such as the cytochrome-b5
reductase pathway in red blood cells (responsible for the
majority of reduction), NADPH methemoglobin reductase
pathway, as well as the ascorbic acid and glutathione en-
zyme systems. When we are exposed to a strong oxidative
agent or large quantities of these agents, methemoglobin
levels rise and methemoglobinemia occurs, when these
protective pathways become saturated and/or deficient.
In newborns cytochrome-b5 reductase pathway is not yet
completely developed, which makes these children more
prone to the accumulation of excess methemoglobin (8,
10). Typical clinical features of methemoglobinemia are
cyanosis, confusion, anxiety, headache, and tachycardia.
These may be present in methemoglobin levels > 10%.
Other signs are an alteration of skin color and brownish
color of the blood. Blood levels > 50% may induce seizures,
coma and levels > 70% are usually fatal. Diagnosis is made
using hemoglobin oximetry, which is available on stan-
dard arterial blood gas analysis (11). Treatment should be
considered when methemoglobin levels are > 20% and/or
when patients are symptomatic (or when levels are > 10%
if risk factors are present such as anemia or ischemic heart
disease). First line treatment consists of IV methylene blue,
which acts as a cofactor for nicotinamide adenine dinu-
cleotide (NADH) methemoglobin reductase (cytochrome-
b5 reductase), rendering methemoglobin back to its nor-
mal form (12). High doses of ascorbic acid can also be
used as a second line therapy because it is an effective
anti-oxidizing agent (13). Most case reports with ascorbic
acid were settings, where methylene blue was not read-
ily available. Second line treatment options are hyper-
baric oxygen therapy and exchange transfusion in patients
who do not respond to methylene blue therapy (14). The
scarcity of literature on this subject is striking. There are
four cases of paracetamol induced methemoglobinemia
in the literature. Despite its frequent use as an analgesic
drug (and frequent use in intoxication), the occurrence of
significant methemoglobinemia seems to be rare. There
is somewhat more literature available on this subject in
veterinary medicine (more specifically in cats and dogs).
However, since the pathophysiologic mechanisms leading
to disease in these animals are somewhat different com-
pared with those in humans, we will not discuss the de-
tails of these cases (15-18). In humans however, the first re-
port dates back to 1968 when a case report was published
in the British Medical Journal describing a case of methe-
moglobinemia after intake of a normal dose of paraceta-
mol for post-partum pain. The level of methemoglobin is
not mentioned in this case report. The patient made an
uneventful recovery (6). In 2000, another survived case
of methemoglobinemia was described in Japan, which re-
ported an initial methemoglobin level of 57%; however,
this case described a combined use of paracetamol and
sodium nitrate (5). The most recent reports are comprised
of Kanji et al. who reported a similar case to ours, describ-
ing a patient with coma, metabolic acidosis, and methe-
moglobinemia after a paracetamol intoxication and re-
ported a methemoglobin level of 9.4%, while no acute liver
failure was found (4) and Queiros et al. who reported
methemoglobinemia (3, 3%) in a hemodialysis-dependent
patient with daily use of 1g paracetamol 3 times a day (3).
As it can be seen, the levels of methemoglobin referred to
in these recent reports are remarkably lower than the level
in our report, which peaked at 24.6%. We assume that in-
gestion of larger quantities of paracetamol and the pres-
ence of acute liver failure (with depletion of glutathione
storages) may have resulted in higher levels of methe-
moglobin in our case. However, why this does not occur
in all patients after paracetamol intoxication with acute
liver failure remains unclear. We did not find any other re-
ports of survival in patients with such high levels of methe-
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moglobinemia associated with paracetamol ingestion.
The exact pathogenesis of paracetamol-induced
methemoglobinemia is not well understood. Since parac-
etamol is a metabolite of acetanilide, which is an aniline
derivate - and one of the first analgesic drugs on the mar-
ket - that was banished because of its important toxicity,
the mechanism in current paracetamol intoxications
could be related and the causative molecule could be
phenylhydrolamine, which is an oxidant metabolite of
these aniline derivatives (18). The reason why this can be
more toxic in some patients is not well understood and
genetic traits could be a key factor in this subject. It is likely
that methemoglobinemia in paracetamol intoxication
is under-diagnosed since mild methemoglobinemia is
typically subclinical. Measuring levels of methemoglobin
is not traditionally included in the standard work-up of
a patient with a paracetamol intoxication. Mild methe-
moglobinemia itself is subclinical and emphasis on
patients with paracetamol intoxication lies typically on
the risk and prevention of acute liver failure (19). It might
also be important to realize paracetamol could also be a
contributing factor to the severity of methemoglobine-
mia caused by other agents. As paracetamol is one of the
most frequently used over-the-counter pharmacological
agents in suicide attempts, the importance of a better
understanding of its toxicity and the mechanisms by
which this toxicity occurs are paramount for ensuring the
best treatment for these patients. Therefore, we advocate
one-off hemoglobin oximetry in all patients with a severe
paracetamol intoxication. Furthermore, clinicians should
have a suspicion for methemoglobinemia in patients with
hypoxia that does not improve with an increased fraction
of inspired oxygen (FiO2), abnormal coloration of blood or
skin or new onset cyanosis after ingestion of an unknown
agent.
3.1. Conclusions
In the present report, a case of survival after
paracetamol-induced methemoglobinemia was pre-
sented. Due to abnormal blood and skin color, the diag-
nosis was confirmed by hemoglobin oximetry. Treatment
with IV methylene blue, ascorbic acid, exchange trans-
fusion, and riboflavin was given with beneficial clinical
effect and decline of the methemoglobin to normal levels.
Paracetamol induced methemoglobinemia seems to be
rare in humans, but may also be under-diagnosed. With
this case report, we would like to focus the attention on the
possibility of methemoglobinemia associated with parac-
etamol intoxication and emphasize the possible impact
on morbidity and mortality. Therefore, there should be a
low threshold for screening for this rare but hazardous
problem, when there is clinical suspicion. Furthermore,
our suggestion would be to evaluate the possible advan-
tages of systematic screening for methemoglobinemia in
paracetamol intoxications in future studies.
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